当前位置:首页 - 行情中心 - 申联生物(688098) - 财务分析 - 利润表

申联生物

(688098)

  

流通市值:43.86亿  总市值:43.86亿
流通股本:4.11亿   总股本:4.11亿

利润表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、营业总收入121,725,138.2878,741,129.63303,414,652.03248,302,819.25
  营业收入121,725,138.2878,741,129.63303,414,652.03248,302,819.25
二、营业总成本138,536,976.1180,804,394.1329,503,695.54259,262,501.74
  营业成本50,158,462.4232,384,277.78120,611,552.5296,550,396.54
  税金及附加2,180,461.071,135,772.064,364,696.613,321,252.96
  销售费用38,625,005.4622,085,481.84100,672,153.2977,225,498.63
  管理费用27,418,489.414,136,293.8655,234,455.5844,995,343.8
  研发费用20,213,006.6311,111,043.5449,355,062.6937,754,809.62
  财务费用-58,448.87-48,474.98-734,225.15-584,799.81
  其中:利息费用136,378.6668,249.9917,062.5-
  其中:利息收入227,198.91131,664.05810,938.91616,342.74
三、其他经营收益
  加:公允价值变动收益2,157,584.14939,856.26883,276.87-35,982.52
  加:投资收益42,443.37395,061.421,785,944.861,418,148.9
  资产处置收益-46,839.3-35,769.23-
  资产减值损失(新)12,977.32-13,753.64-28,177,425.29-18,409.77
  信用减值损失(新)-4,530,675.3-4,234,970.81-8,471,632.6-12,215,863.03
  其他收益2,795,434.63850,483.613,522,429.882,848,837.55
四、营业利润-16,380,912.97-4,126,587.63-56,510,680.56-18,962,951.36
  加:营业外收入119,601023,304.3266,882.31
  减:营业外支出3,221.413,221.41306,945.28309,101.48
五、利润总额-16,264,533.38-4,129,809.04-56,794,321.52-19,205,170.53
  减:所得税费用-1,222,141.6-75,203.57-8,045,757.13-2,184,727.05
六、净利润-15,042,391.78-4,054,605.47-48,748,564.39-17,020,443.48
(一)按经营持续性分类
  持续经营净利润-15,042,391.78-4,054,605.47-48,748,564.39-17,020,443.48
(二)按所有权归属分类
  归属于母公司股东的净利润-12,869,700.94-3,019,866.61-44,740,058.21-14,124,681.4
  少数股东损益-2,172,690.84-1,034,738.86-4,008,506.18-2,895,762.08
  扣除非经常损益后的净利润-16,796,202.06-4,450,133.9-48,376,509.32-15,541,748.72
七、每股收益
  (一)基本每股收益-0.03-0.01-0.11-0.03
  (二)稀释每股收益-0.03-0.01-0.11-0.03
九、综合收益总额-15,042,391.78-4,054,605.47-48,748,564.39-17,020,443.48
  归属于母公司股东的综合收益总额-12,869,700.94-3,019,866.61-44,740,058.21-14,124,681.4
  归属于少数股东的综合收益总额-2,172,690.84-1,034,738.86-4,008,506.18-2,895,762.08
公告日期2025-08-302025-04-302025-04-302024-10-31
审计意见(境内)标准无保留意见
TOP↑